In the neuroscience segment, Medtronic reported revenues of $2.45bn for the quarter. Credit: JHVEPhoto / Shutterstock.

Medtronic has reported a net income of $1.27bn for the second quarter (Q2) of fiscal year 2025 (FY 2025), marking a substantial rise from $911m in the same quarter of the previous year.

Net income attributable to the company was reported to be $1.27bn for the period which ended on 25 October 2024, compared to $909m in the prior year, indicating consistent growth.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Worldwide revenue for the quarter reached $8.403bn, an uptick of 5.3% as reported and 5% on an organic basis. 

Diluted earnings per share (EPS) also witnessed a significant leap, with a 46% increase to $0.99.

The cardiovascular portfolio was a strong performer, with revenue climbing to $3.10bn in Q2 FY 2025, up by 6.1% from $2.92bn reported in FY 2024.

In the neuroscience segment, Medtronic reported revenue of $2.45bn for the quarter, a 7.1% increase from $2.28bn in the previous year.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The medical surgical portfolio saw a more modest rise of 1.2% from $2.10bn last year to $2.12bn this year.

The company’s diabetes portfolio demonstrated impressive growth with revenues surging by 12.4% to $686m in FY 2025 from $610m in Q2 of the previous year.

Non-GAAP net income and diluted EPS stood at $1.620bn and $1.26 respectively, representing a 3% decrease and a 1% increase, respectively.  

Medtronic chairman and CEO Geoff Martha said: “Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations.

“As we look ahead, we’re confident that this diversified growth will keep going, especially given the strength of our pipeline in high-impact markets that will allow us to benefit even more patients around the world.”